Tower Research Capital LLC (Trc) Atea Pharmaceuticals, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 3,617 shares of AVIR stock, worth $11,248. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,617
Previous 11,734
69.18%
Holding current value
$11,248
Previous $39,000
69.23%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding AVIR
# of Institutions
108Shares Held
53.9MCall Options Held
900Put Options Held
126K-
Black Rock Inc. New York, NY9.12MShares$28.4 Million0.0% of portfolio
-
Bml Capital Management, LLC Zionsville, IN7.61MShares$23.7 Million15.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.67MShares$14.5 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA4.61MShares$14.3 Million1.31% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.34MShares$10.4 Million0.52% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $259M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...